PSMAI cut-off value for mortality in men: 680.1 mm2/m2

Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu- PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

Trends in Premature Mortality From Acute Myocardial Infarction in the United States, 1999 to 2019

Dual-Time-Point Posttherapy 177Lu-PSMA-617 SPECT/CT Describes the Uptake Kinetics of mCRPC Lesions and Prognosticates Patients' Outcome

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

ASCO 2022: PRINCE: Phase I Trial of 177Lu-PSMA-617 in Combination with Pembrolizumab in Patients with mCRPC

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands

Reduced Acquisition Time per Bed Position for PET/MRI Using 68Ga-RM2 or 68Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis

The Current Landscape of Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy

Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study - ScienceDirect